Cronos Group Inc (CRON)vsUnited Therapeutics Corporation (UTHR)
CRON
Cronos Group Inc
$3.14
-0.63%
HEALTHCARE · Cap: $1.16B
UTHR
United Therapeutics Corporation
$497.11
-1.34%
HEALTHCARE · Cap: $21.36B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 1661% more annual revenue ($3.15B vs $179.09M). UTHR leads profitability with a 41.6% profit margin vs 39.1%. CRON trades at a lower P/E of 16.5x. UTHR earns a higher WallStSmart Score of 61/100 (C+).
CRON
Buy61
out of 100
Grade: C+
UTHR
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CRON.
Margin of Safety
+0.8%
Fair Value
$479.95
Current Price
$497.11
$17.16 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Keeps 39 of every $100 in revenue as profit
Revenue surging 58.4% year-over-year
Earnings expanding 126.8% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 42 of every $100 in revenue as profit
Strong operational efficiency at 42.2%
Safe zone — low bankruptcy risk
Every $100 of equity generates 20 in profit
Attractively priced relative to earnings
Areas to Watch
Smaller company, higher risk/reward
ROE of -0.2% — below average capital efficiency
Expensive relative to growth rate
Revenue declined 1.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : CRON
The strongest argument for CRON centers on Price/Book, Profit Margin, Revenue Growth. Profitability is solid with margins at 39.1% and operating margin at 15.4%. Revenue growth of 58.4% demonstrates continued momentum.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 41.6% and operating margin at 42.2%.
Bear Case : CRON
The primary concerns for CRON are Market Cap, Return on Equity.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
CRON profiles as a growth stock while UTHR is a declining play — different risk/reward profiles.
CRON carries more volatility with a beta of 1.28 — expect wider price swings.
CRON is growing revenue faster at 58.4% — sustainability is the question.
UTHR generates stronger free cash flow (206M), providing more financial flexibility.
Bottom Line
CRON scores higher overall (61/100 vs 61/100), backed by strong 39.1% margins and 58.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cronos Group Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Cronos Group Inc. is a cannabinoid company. The company is headquartered in Toronto, Canada.
Visit Website →United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?